PMID- 32486257
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 11
DP  - 2020 May 30
TI  - Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical 
      Implications.
LID - 10.3390/ijms21113930 [doi]
LID - 3930
AB  - Dendritic cells (DCs) constitute a complex network of cell subsets with common 
      functions but also with many divergent aspects. All dendritic cell subsets share 
      the ability to prime T cell response and to undergo a complex trafficking program 
      related to their stage of maturation and function. For these reasons, dendritic 
      cells are implicated in a large variety of both protective and detrimental immune 
      responses, including a crucial role in promoting anti-tumor responses. Although 
      cDC1s are the most potent subset in tumor antigen cross-presentation, they are 
      not sufficient to induce full-strength anti-tumor cytotoxic T cell response and 
      need close interaction and cooperativity with the other dendritic cell subsets, 
      namely cDC2s and pDCs. This review will take into consideration different aspects 
      of DC biology, including the functional role of dendritic cell subsets in both 
      fostering and suppressing tumor growth, the mechanisms underlying their 
      recruitment into the tumor microenvironment, as well as the prognostic value and 
      the potentiality of dendritic cell therapeutic targeting. Understanding the 
      specificity of dendritic cell subsets will allow to gain insights on role of 
      these cells in pathological conditions and to design new selective promising 
      therapeutic approaches.
FAU - Del Prete, Annalisa
AU  - Del Prete A
AD  - Department of Molecular and Translational Medicine, University of Brescia, Viale 
      Europa 11, 25123 Brescia, Italy.
AD  - Humanitas Clinical and Research Center - IRCCS, Via Manzoni 56, 20089 Rozzano 
      (MI), Italy.
FAU - Sozio, Francesca
AU  - Sozio F
AD  - Department of Molecular and Translational Medicine, University of Brescia, Viale 
      Europa 11, 25123 Brescia, Italy.
AD  - Humanitas Clinical and Research Center - IRCCS, Via Manzoni 56, 20089 Rozzano 
      (MI), Italy.
FAU - Barbazza, Ilaria
AU  - Barbazza I
AD  - Department of Molecular and Translational Medicine, University of Brescia, Viale 
      Europa 11, 25123 Brescia, Italy.
FAU - Salvi, Valentina
AU  - Salvi V
AD  - Department of Molecular and Translational Medicine, University of Brescia, Viale 
      Europa 11, 25123 Brescia, Italy.
FAU - Tiberio, Laura
AU  - Tiberio L
AD  - Department of Molecular and Translational Medicine, University of Brescia, Viale 
      Europa 11, 25123 Brescia, Italy.
FAU - Laffranchi, Mattia
AU  - Laffranchi M
AD  - Department of Molecular and Translational Medicine, University of Brescia, Viale 
      Europa 11, 25123 Brescia, Italy.
FAU - Gismondi, Angela
AU  - Gismondi A
AD  - Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, 
      Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 
      291, 00161 Rome, Italy.
FAU - Bosisio, Daniela
AU  - Bosisio D
AD  - Department of Molecular and Translational Medicine, University of Brescia, Viale 
      Europa 11, 25123 Brescia, Italy.
FAU - Schioppa, Tiziana
AU  - Schioppa T
AD  - Department of Molecular and Translational Medicine, University of Brescia, Viale 
      Europa 11, 25123 Brescia, Italy.
AD  - Humanitas Clinical and Research Center - IRCCS, Via Manzoni 56, 20089 Rozzano 
      (MI), Italy.
FAU - Sozzani, Silvano
AU  - Sozzani S
AD  - Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, 
      Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 
      291, 00161 Rome, Italy.
LA  - eng
GR  - IG 2017 - ID 20776/Associazione Italiana per la Ricerca sul Cancro/
GR  - 20177J4E75/MIUR-PRIN 2017/
PT  - Journal Article
PT  - Review
DEP - 20200530
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Antineoplastic Agents/pharmacology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cell Movement
MH  - Chemokines/immunology
MH  - Cytokines/immunology
MH  - Dendritic Cells/*immunology
MH  - Disease Progression
MH  - Homeostasis
MH  - Humans
MH  - Immunophenotyping
MH  - Immunosuppressive Agents/pharmacology
MH  - Immunotherapy
MH  - Mice
MH  - Neoplasms/immunology/*pathology
MH  - Prognosis
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Treatment Outcome
MH  - Tumor Microenvironment
PMC - PMC7312661
OTO - NOTNLM
OT  - cancer
OT  - cancer immunotherapy
OT  - chemokines
OT  - cytokines
OT  - dendritic cell subsets
OT  - migration
OT  - tumor microenvironment
COIS- The authors declare no conflict of interest.
EDAT- 2020/06/04 06:00
MHDA- 2021/04/01 06:00
PMCR- 2020/06/01
CRDT- 2020/06/04 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
PHST- 2020/06/01 00:00 [pmc-release]
AID - ijms21113930 [pii]
AID - ijms-21-03930 [pii]
AID - 10.3390/ijms21113930 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 May 30;21(11):3930. doi: 10.3390/ijms21113930.